Does Rallies show Form 4 insider transactions for XGN?

Yes. Rallies tracks XGN insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is XGN research on Rallies investment advice?

No. Rallies provides research, data, and educational context for XGN. It does not provide personalized investment advice.

XGN (Exagen Inc. Common Stock) Stock Analysis - Insider Trades

Exagen Inc. Common Stock (XGN) is a publicly traded Healthcare sector company. As of May 21, 2026, XGN trades at $3.83 with a market cap of $84.32M and a P/E ratio of -4.24. XGN moved +2.95% today. Year to date, XGN is -35.63%; over the trailing twelve months it is -35.74%. Its 52-week range spans $2.38 to $12.23. Analyst consensus is strong buy with an average price target of $8.67. Rallies surfaces XGN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading XGN stock inside the company?

Recent XGN insider activity includes ABALLI JOHN sold 15.70K, ABALLI JOHN sold 11.43K, Black Jeffrey G. sold 1.58K, ABALLI JOHN sold 31.79K, and Black Jeffrey G. sold 20.47K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

XGN Key Metrics

Key financial metrics for XGN
Metric	Value
Price	$3.83
Market Cap	$84.32M
P/E Ratio	-4.24
EPS	$-0.89
Dividend Yield	0.00%
52-Week High	$12.23
52-Week Low	$2.38
Volume	0
Avg Volume	0
Revenue (TTM)	$68.38M
Net Income	$-20.17M
Gross Margin	58.32%

Recent XGN Insider Trades

ABALLI JOHN sold 15.70K (~$56.83K) on Mar 3, 2026.
ABALLI JOHN sold 11.43K (~$41.26K) on Feb 24, 2026.
Black Jeffrey G. sold 1.58K (~$5.72K) on Feb 24, 2026.
ABALLI JOHN sold 31.79K (~$375.60K) on Oct 16, 2025.
Black Jeffrey G. sold 20.47K (~$200.36K) on Sep 2, 2025.

Latest XGN News

Exagen Reports Record Q1 2026 Revenue, Unveils Strategic Growth Plans — May 12, 2026
Exagen Posts Record Quarterly Revenue Growth with Higher Test Pricing, Losses Persist — May 11, 2026
Exagen first-quarter revenue up 12% to $17.3M; ASP climbs 6% to $444 — May 11, 2026
Exagen Inc. Posts 20% Revenue Growth, Raises R&D and Commercial Costs 13% — Mar 10, 2026
Exagen Inc. Q4 Loss of $0.20 Expected as EPS Estimates Fall 24% — Feb 26, 2026

XGN Analyst Consensus

7 analysts cover XGN: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $8.67.

Common questions about XGN

Who is trading XGN stock inside the company?: Recent XGN insider activity includes ABALLI JOHN sold 15.70K, ABALLI JOHN sold 11.43K, Black Jeffrey G. sold 1.58K, ABALLI JOHN sold 31.79K, and Black Jeffrey G. sold 20.47K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for XGN?: Yes. Rallies tracks XGN insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is XGN research on Rallies investment advice?: No. Rallies provides research, data, and educational context for XGN. It does not provide personalized investment advice.